Premium
Pediatric Oncology Group Utilization of Immunologic Markers in the Designation of Acute Lymphocytic Leukemia Subgroups: Influence on Treatment Response a
Author(s) -
PULLEN D. JEANETTE,
BOYETT JAMES M.,
CRIST WILLIAM M.,
FALLETTA JOHN M.,
ROPER MARYANN,
DOWELL BARRY,
EYS JAN,
JACKSON JOHN F.,
HUMPHREY G. BENNETT,
METZGAR RICHARD S.,
COOPER MAX D.
Publication year - 1984
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1984.tb12280.x
Subject(s) - medicine , medical school , annals , family medicine , library science , pediatrics , history , medical education , classics , computer science
The clinical application of blast cell immunophenotype testing is important in childhood ALL for the following reasons. (1) Knowledge of the immunologic group is important in predicting prognosis. Prognostic grouping may prove to be accomplished best by using a combination of traditional risk factors and immunologic phenotyping. However, definition of traditional risk factors may vary within the immunologic groups of ALL. (2) In assessing the relative effectiveness of different treatment regimens for children with ALL it is important to make comparisons among patients within the same major immunologic groups of ALL. (3) Identification of specific immunologic groups of patients within ALL may help in designing therapy for each group. The POG has already made preliminary attempts in this direction for T-ALL and B-ALL. However, leukemia species-specific therapy is still only a long-range goal. Laboratory research must endeavor to identify additional biologic characteristics peculiar to each major immunologic group of ALL. These characteristics may dictate therapeutic maneuvers in the future.